Pharmacological Disruption of the BRCA2–RAD51 Interface: Inducing BRCAness to Exploit Synthetic Lethality in Homologous-Recombination-Proficient Cancer

Homologous recombination is a high-fidelity DNA repair pathway that preserves genome integrity during replication stress and double-strand break repair. Central to it is the BRCA2–RAD51 axis, in which BRCA2 coordinates RAD51 recruitment, nucleoprotein filament assembly and protection of recombination intermediates. PARP inhibitors have validated synthetic lethality in BRCA-deficient cancers, but their benefit requires pre-existing homologous-recombination deficiency and is limited by acquired resistance. Pharmacological disruption of the BRCA2–RAD51 interface offers a route to a reversible “BRCAness” state in homologous-recombination-proficient tumors. This review examines the structural basis of BRCA2-mediated RAD51 control, the small-molecule disruptors reported to date—triazoles, dihydroquinolone pyrazolines, CAM833, N-acylhydrazones, fragment-derived compounds and quinoline-based analogs—and the peptide, D-amino-acid and aptamer modalities targeting the same axis, together with combination evidence, pancreatic cancer as the dominant disease model, pharmacodynamic biomarkers, selectivity and resistance. Because reported potencies derive from heterogeneous protein constructs and assay formats, the construct used is stated for every value and biochemical and cellular potencies are tabulated separately, and each agent is classified explicitly as a mechanistic probe or an early lead. We emphasize three limitations that the field has not yet addressed: no interface disruptor of any modality has completed in vivo pharmacokinetic–pharmacodynamic characterization, unbound tissue exposure and the reversibility of homologous-recombination inhibition are unmeasured, and peptide and oligonucleotide agents face unresolved barriers of nuclear delivery, proteolytic or nucleolytic degradation, biodistribution and innate immune activation. BRCA2–RAD51 interface disruption is therefore a mechanistically rational but strictly preclinical strategy whose feasibility will be decided by in vivo exposure–response and tolerability data that do not yet exist.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-11-16
DOI
https://doi.org/10.3390/ph19111823
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacological Disruption of the BRCA2–RAD51 Interface: Inducing BRCAness to Exploit Synthetic Lethality in Homologous-Recombination-Proficient Cancer

Fahad M. Alshabrmi
Pharmaceuticals
PARP inhibition in cancer therapy
article

Pharmacological Disruption of the BRCA2–RAD51 Interface: Inducing BRCAness to Exploit Synthetic Lethality in Homologous-Recombination-Proficient Cancer

Fahad M. Alshabrmi
article en

Abstract

Homologous recombination is a high-fidelity DNA repair pathway that preserves genome integrity during replication stress and double-strand break repair. Central to it is the BRCA2–RAD51 axis, in which BRCA2 coordinates RAD51 recruitment, nucleoprotein filament assembly and protection of recombination intermediates. PARP inhibitors have validated synthetic lethality in BRCA-deficient cancers, but their benefit requires pre-existing homologous-recombination deficiency and is limited by acquired resistance. Pharmacological disruption of the BRCA2–RAD51 interface offers a route to a reversible “BRCAness” state in homologous-recombination-proficient tumors. This review examines the structural basis of BRCA2-mediated RAD51 control, the small-molecule disruptors reported to date—triazoles, dihydroquinolone pyrazolines, CAM833, N-acylhydrazones, fragment-derived compounds and quinoline-based analogs—and the peptide, D-amino-acid and aptamer modalities targeting the same axis, together with combination evidence, pancreatic cancer as the dominant disease model, pharmacodynamic biomarkers, selectivity and resistance. Because reported potencies derive from heterogeneous protein constructs and assay formats, the construct used is stated for every value and biochemical and cellular potencies are tabulated separately, and each agent is classified explicitly as a mechanistic probe or an early lead. We emphasize three limitations that the field has not yet addressed: no interface disruptor of any modality has completed in vivo pharmacokinetic–pharmacodynamic characterization, unbound tissue exposure and the reversibility of homologous-recombination inhibition are unmeasured, and peptide and oligonucleotide agents face unresolved barriers of nuclear delivery, proteolytic or nucleolytic degradation, biodistribution and innate immune activation. BRCA2–RAD51 interface disruption is therefore a mechanistically rational but strictly preclinical strategy whose feasibility will be decided by in vivo exposure–response and tolerability data that do not yet exist.

PharmaceuticalsVol. 19(11)
Qassim University (SA)
Good health and well-being
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon